Related Experiment Video
Updated: Apr 12, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
A review of the pathophysiology and potential biomarkers for peripheral artery disease
Smriti Murali Krishna1, Joseph V Moxon2, Jonathan Golledge3,4
1The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine & Dentistry, James Cook University, Townsville, QLD 4811, Australia. smriti.krishna@jcu.edu.au.
Insights
Peripheral artery disease (PAD) management needs improvement. Circulating biomarkers may help predict PAD progression and treatment response, guiding better patient care and potentially reducing amputations.
Area of Science:
- Vascular Medicine
- Biomarker Discovery
- Atherosclerosis Research
Background:
- Peripheral artery disease (PAD) involves lower limb artery blockages, often from atherosclerosis.
- Critical limb ischemia (CLI), the severe form of PAD, carries risks of limb loss and cardiovascular mortality.
- Current treatments like revascularization have limitations, leading to repeated procedures and amputations.
Purpose of the Study:
- To review PAD pathophysiology.
- To examine the link between circulating biomarkers and PAD.
- To assess biomarkers for predicting PAD presence, severity, and prognosis.
Main Methods:
- Literature review of PAD pathophysiology.
- Analysis of studies on circulating biomarkers in PAD patients.
- Evaluation of biomarker associations with PAD presence, severity, and outcomes.
Main Results:
- Current PAD management faces challenges in patient selection and treatment efficacy.
- Circulating biomarkers show potential for predicting PAD progression and therapy response.
- Existing biomarkers require further validation in larger studies.
Conclusions:
- Improved methods are needed to identify patients unlikely to benefit from revascularization.
- Circulating biomarkers could enhance PAD patient management and treatment selection.
- Larger studies are necessary to confirm the clinical utility of biomarkers over current risk predictors.
Abstract:
Peripheral artery disease (PAD) is due to the blockage of the arteries supplying blood to the lower limbs usually secondary to atherosclerosis. The most severe clinical manifestation of PAD is critical limb ischemia (CLI), which is associated with a risk of limb loss and mortality due to cardiovascular events. Currently CLI is mainly treated by surgical or endovascular revascularization, with few other treatments in routine clinical practice. There are a number of problems with current PAD management strategies, such as the difficulty in selecting the appropriate treatments for individual patients. Many patients undergo repeated attempts at revascularization surgery, but ultimately require an amputation. There is great interest in developing new methods to identify patients who are unlikely to benefit from revascularization and to improve management of patients unsuitable for surgery. Circulating biomarkers that predict the progression of PAD and the response to therapies could assist in the management of patients. This review provides an overview of the pathophysiology of PAD and examines the association between circulating biomarkers and PAD presence, severity and prognosis. While some currently identified circulating markers show promise, further larger studies focused on the clinical value of the biomarkers over existing risk predictors are needed.
Related Concept Videos
Peripheral Artery Disease I: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Peripheral Artery Disease IV: Nursing Management
Peripheral Artery Disease III: Interprofessional Care

